Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction

In conclusion, dapagliflozin is an effective and generally well-tolerated treatment that represents a valuable new addition to the options available for symptomatic HFrEF.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research